<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519270</url>
  </required_header>
  <id_info>
    <org_study_id>IGN002-101</org_study_id>
    <nct_id>NCT02519270</nct_id>
  </id_info>
  <brief_title>Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects</brief_title>
  <acronym>NHL</acronym>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunGene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunGene, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and
      Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with
      Refractory Non-Hodgkin Lymphoma (NHL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, non-randomized, first-in-human Phase 1 study involves two stages:

      In the Dose-Escalation Stage, ascending dose cohorts will be treated in 2 periods until the
      maximum tolerated dose is identified. In Period 1, subjects will receive 2 doses of IGN002
      administered weekly. In Period 2, subjects will receive up to 24 additional doses of IGN002
      administered weekly in three 8-week cycles. Subjects that have not progressed following the
      treatment period will be followed for another 6 months.

      In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the identified
      maximum tolerated dose administered weekly in three 8-week cycles. Subjects that have not
      progressed following the treatment period will be followed for another 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of multiple doses of IGN002 administered weekly as an intravenous (IV) infusion to subjects with refractory NHL</measure>
    <time_frame>Weekly for 6 months</time_frame>
    <description>Adverse Event collection and assessment will be done for all potentially treated subjects to assess the safety, tolerability, and determine the maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of ascending doses of IGN002 administered weekly</measure>
    <time_frame>Weekly for 6 months</time_frame>
    <description>Pharmacokinetic (PK) parameters such as Maximum concentration (Cmax), time to maximum concentration (Tmax), minimum concentration(Cmin), area under the curve (AUC), half-life (t1/2), clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the anti-tumor activity of IGN002 using the Lugano Classification for NHL</measure>
    <time_frame>Every 8 weeks for 6 months, then at 1, 3 and 6 months</time_frame>
    <description>Determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in NHL patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGN002</intervention_name>
    <description>IGN002 is a monoclonal antibody fusion protein.</description>
    <arm_group_label>Dose Escalation Stage</arm_group_label>
    <arm_group_label>Expansion Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history of immunohistochemistry (IHC)-confirmed CD20-positive (with no
             subsequent history of CD20-negativity) B-cell, NHL, including diffuse large B cell
             (DLBCL), mantle cell, marginal zone, lymphoplasmacytic, follicular, transformed
             follicular, or primary mediastinal B cell lymphoma

          -  Refractory disease, having failed available therapies

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy &gt; 3 months

          -  Adequate organ function

        Exclusion Criteria:

          -  Treatment with an approved or investigational chemotherapy drug within 28 days of Day
             1

          -  Treatment with an approved or investigational anti-CD20 drug within 28 days of Day 1

          -  Treatment with an approved or investigational biologic drug that does not target CD20
             within 90 days of Day 1

          -  Radiation therapy within 4 weeks of Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Khare, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunGene, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>(877) 777-9233</phone>
    <phone_ext>703</phone_ext>
    <email>clinical@immungene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bessie Bautista</last_name>
      <phone>310-570-1457</phone>
      <email>bbautista@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Timmerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashton Monismith</last_name>
      <phone>352-273-7832</phone>
      <email>amonismith@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Nam Dang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chizobam &quot;Chi Chi&quot; Obi</last_name>
      <phone>713-794-3074</phone>
      <email>CIObi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Loretta Nastoupil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

